Moxifloxacin

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic with enhanced bactericidal activity against Gram-positive bacteria (including penicillin-resistant Streptococcus pneumoniae) and anaerobes, alongside standard Gram-negative coverage. It does not require dosage adjustments in renal impairment because it is eliminated primarily by hepatic glucuronide and sulfate conjugation. Indicated for community-acquired pneumonia, acute bacterial sinusitis, complicated intra-abdominal infections, and second-line MDR-TB regimens.

Moxifloxacin Hydrochloride (0.5% w/v ophthalmic solution) is a fourth-generation fluoroquinolone broad-spectrum bactericidal eye drop on the WHO Model List of Essential Medicines. It simultaneously inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, demonstrating high corneal tissue penetration, low resistance rates, and exceptional potency against Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), and Gram-negative ocular pathogens. Self-preserved formulation eliminates the need for epithelial-toxic preservatives like benzalkonium chloride. Indicated for bacterial conjunctivitis and peri-operative prophylaxis in intraocular surgeries.

Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.

Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.

Cefixime and Moxifloxacin combination pairs a 3rd-generation oral cephalosporin with a respiratory fluoroquinolone. Provides enhanced dual coverage against typical and atypical respiratory pathogens, resistant Gram-negative bacilli, and anaerobes. Indicated for severe or refractory community-acquired pneumonia, acute exacerbations of chronic bronchitis, and complicated polymicrobial infections.

Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.

Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.